Literature DB >> 8638704

Prostaglandin endoperoxide synthase: why two isoforms?

C S Williams1, R N DuBois.   

Abstract

Prostaglandin endoperoxide synthase-1 [prostaglandin G/H synthase-1 (PGHS-1)] and PGHS-2 are key enzymes in the conversion of arachidonic acid to prostaglandins and other eicosanoids. We refer to these isoforms as cyclooxygenase-1 (COX-1) and COX-2 in this review. This brief review focuses on recent developments in the study of these enzymes. Alterations in the expression levels of COX-2 result in distinct phenotypic changes in intestinal epithelial cells. Overexpression of COX-2 in intestinal epithelial cells results in increased adhesion to extracellular matrix proteins and inhibition of apoptosis. Disruption of the COX-2 gene in mice results in renal dysplasia, cardiac fibrosis, and defects in the ovary. Interestingly, disruption of the COX-1 gene results in distinct phenotypic changes different from those observed for COX-2. COX-1 null mice survive well, have no gastric pathology, and show less indomethacin-induced gastric ulceration than wild-type mice. These two closely related enzymes must have distinct functions in the organisms, since lack of their expression causes distinct phenotypic changes for each respective isoform.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8638704     DOI: 10.1152/ajpgi.1996.270.3.G393

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  86 in total

1.  Cytotoxic necrotizing factor from Escherichia coli induces RhoA-dependent expression of the cyclooxygenase-2 Gene.

Authors:  W Thomas; Z K Ascott; D Harmey; L W Slice; E Rozengurt; A J Lax
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

2.  Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells.

Authors:  D Saha; P K Datta; H Sheng; J D Morrow; M Wada; H L Moses; R D Beauchamp
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

3.  Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors.

Authors:  T Koshiba; R Hosotani; Y Miyamoto; M Wada; J U Lee; K Fujimoto; S Tsuji; S Nakajima; R Doi; M Imamura
Journal:  Int J Pancreatol       Date:  1999-10

4.  Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer.

Authors:  Brian M Kennedy; Randall E Harris
Journal:  Inflammopharmacology       Date:  2018-05-07       Impact factor: 4.473

Review 5.  Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.

Authors:  Onder Onguru; Mary B Casey; Sabine Kajita; Nobuki Nakamura; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

6.  Flipping the cyclooxygenase (Ptgs) genes reveals isoform-specific compensatory functions.

Authors:  Xinzhi Li; Liudmila L Mazaleuskaya; Chong Yuan; Laurel L Ballantyne; Hu Meng; William L Smith; Garret A FitzGerald; Colin D Funk
Journal:  J Lipid Res       Date:  2017-11-27       Impact factor: 5.922

Review 7.  The role of apoptosis in intestinal disease.

Authors:  A J Watson
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

8.  Expression of cyclooxygenase-2 in human esophageal squamous cell carcinomas.

Authors:  Jian-Gang Jiang; Jiang-Bo Tang; Chun-Lian Chen; Bao-Xing Liu; Xiang-Ning Fu; Zhi-Hui Zhu; Wei Qu; Katherine Cianflone; Michael-P Waalkes; Dao-Wen Wang
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

9.  Sinomenine inhibits proliferation of SGC-7901 gastric adenocarcinoma cells via suppression of cyclooxygenase-2 expression.

Authors:  Yifei Lv; Changshun Li; Shuang Li; Zhiming Hao
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

10.  The identification of salicylates as normal constituents of serum: a link between diet and health?

Authors:  J R Paterson; C Blacklock; G Campbell; D Wiles; J R Lawrence
Journal:  J Clin Pathol       Date:  1998-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.